Skip to the content

Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC)

Casaburi, I, Avena, P, De Luca, A, Chimento, A, Sirianni, R, Malivindi, R, Rago, V, Fiorillo, M, Domanico, F, Campana, C, Cappello, A, Sotgia, Federica, Lisanti, M and Pezzi, V 2015, 'Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC)' , Oncotarget, 6 (28) , pp. 25135-25148.

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview

Abstract

The pathogenesis of the adrenocortical cancer (ACC) involves integration of molecular signals and the interplay of different downstream pathways (i.e. IGFII/IGF1R, β-catenin, Wnt, ESR1). This tumor is characterized by limited therapeutic options and unsuccessful treatments. A useful strategy to develop an effective therapy for ACC is to identify a common downstream target of these multiple pathways. A good candidate could be the transcription factor estrogen-related receptor alpha (ERRα) because of its ability to regulate energy metabolism, mitochondrial biogenesis and signalings related to cancer progression. In this study we tested the effect of ERRα inverse agonist, XCT790, on the proliferation of H295R adrenocortical cancer cell line. Results from in vitro and in vivo experiments showed that XCT790 reduced H295R cell growth. The inhibitory effect was associated with impaired cell cycle progression which was not followed by any apoptotic event. Instead, incomplete autophagy and cell death by a necrotic processes, as a consequence of the cell energy failure, induced by pharmacological reduction of ERRα was evidenced. Our results indicate that therapeutic strategies targeting key factors such as ERRα that control the activity and signaling of bioenergetics processes in high-energy demanding tumors could represent an innovative/alternative therapy for the treatment of ACC.

Item Type: Article
Schools: Schools > School of Environment and Life Sciences > Biomedical Research Centre
Journal or Publication Title: Oncotarget
Publisher: Impact Journals
ISSN: 1949-2553
Related URLs:
Funders: Funder not known
Depositing User: Federica Sotgia
Date Deposited: 29 Jun 2016 08:31
Last Modified: 29 Jun 2016 08:31
URI: http://usir.salford.ac.uk/id/eprint/39279

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)

Downloads

Downloads per month over past year